PMID- 35461782
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20230124
IS  - 1873-5010 (Electronic)
IS  - 1569-1993 (Print)
IS  - 1569-1993 (Linking)
VI  - 21
IP  - 3
DP  - 2022 May
TI  - Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults 
      with cystic fibrosis.
PG  - e184-e187
LID - S1569-1993(22)00094-7 [pii]
LID - 10.1016/j.jcf.2022.04.004 [doi]
AB  - Data regarding immunogenicity of SARS-CoV-2 BNT162b2 vaccine in cystic fibrosis 
      (CF) patients are limited. We prospectively measured total (TAbs-RBD; U/ml) and 
      neutralizing (NAbs-RBD; %) antibodies of SARS-CoV-2 spike-receptor binding domain 
      (RBD) protein in 33 CF patients and 66 healthy controls with median age (IQR): 
      19.6 (17.6-24.3) years and 31 (29-36) years, respectively and investigated 
      possible associations with epidemiological and clinical parameters. Compared to 
      healthy controls, CF patients had higher levels of TAbs-RBD and NAbs-RBD after 
      both doses (P-value < 0.001). One month after the second dose, CF patients and 
      controls had TAbs-RBD: median (IQR): 3396 (2443) and 1452 (1231) U/ml, 
      respectively. Similarly, the NAbs-RBD (%) were: 97.30 (1.00) and 95.70 (3.71) %, 
      respectively. CF patients also had fewer local and systemic adverse events (AEs) 
      (P-value < 0.001). Among CF patients, no significant differences in 
      immunogenicity were detected regarding the phenotype, genotype, medications, or 
      severity of the disease. BNT162b2 vaccine was immunogenic with limited 
      reactogenicity in CF patients regardless of the phenotype or severity of disease.
CI  - Copyright (c) 2022. Published by Elsevier B.V.
FAU - Michos, Athanasios
AU  - Michos A
AD  - First Department of Pediatrics, Infectious Diseases and Chemotherapy Research 
      Laboratory, Medical School, National and Kapodistrian University of Athens, 
      'Aghia Sophia' Children's Hospital, Athens, Greece. Electronic address: 
      amichos@med.uoa.gr.
FAU - Filippatos, Filippos
AU  - Filippatos F
AD  - First Department of Pediatrics, Infectious Diseases and Chemotherapy Research 
      Laboratory, Medical School, National and Kapodistrian University of Athens, 
      'Aghia Sophia' Children's Hospital, Athens, Greece.
FAU - Tatsi, Elizabeth-Barbara
AU  - Tatsi EB
AD  - University Research Institute for Maternal and Child Health and Precision 
      Medicine, Athens, Greece.
FAU - Dellis, Charilaos
AU  - Dellis C
AD  - First Department of Pediatrics, Infectious Diseases and Chemotherapy Research 
      Laboratory, Medical School, National and Kapodistrian University of Athens, 
      'Aghia Sophia' Children's Hospital, Athens, Greece.
FAU - Efthymiou, Vasiliki
AU  - Efthymiou V
AD  - University Research Institute for Maternal and Child Health and Precision 
      Medicine, Athens, Greece.
FAU - Zarkada, Ioanna
AU  - Zarkada I
AD  - Cystic Fibrosis Department, ''Aghia Sophia" Children's Hospital, Athens, Greece.
FAU - Troupi, Evgenia
AU  - Troupi E
AD  - Cystic Fibrosis Department, ''Aghia Sophia" Children's Hospital, Athens, Greece.
FAU - Syriopoulou, Vasiliki
AU  - Syriopoulou V
AD  - First Department of Pediatrics, Infectious Diseases and Chemotherapy Research 
      Laboratory, Medical School, National and Kapodistrian University of Athens, 
      'Aghia Sophia' Children's Hospital, Athens, Greece.
FAU - Loukou, Ioanna
AU  - Loukou I
AD  - Cystic Fibrosis Department, ''Aghia Sophia" Children's Hospital, Athens, Greece.
LA  - eng
PT  - Journal Article
DEP - 20220414
PL  - Netherlands
TA  - J Cyst Fibros
JT  - Journal of cystic fibrosis : official journal of the European Cystic Fibrosis 
      Society
JID - 101128966
RN  - 0 (Antibodies, Viral)
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Vaccines)
RN  - N38TVC63NU (BNT162 Vaccine)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Viral
MH  - BNT162 Vaccine
MH  - *COVID-19/epidemiology/prevention & control
MH  - COVID-19 Vaccines/adverse effects
MH  - *Cystic Fibrosis/epidemiology
MH  - Humans
MH  - SARS-CoV-2
MH  - *Vaccines
MH  - Young Adult
PMC - PMC9008191
OTO - NOTNLM
OT  - Antibody
OT  - BNT162b2
OT  - COVID-19
OT  - Cystic fibrosis
OT  - Neutralizing
OT  - SARS-CoV-2
OT  - Vaccine
COIS- Declaration of Competing Interest None.
EDAT- 2022/04/25 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/04/14
CRDT- 2022/04/24 20:21
PHST- 2022/01/21 00:00 [received]
PHST- 2022/03/28 00:00 [revised]
PHST- 2022/04/04 00:00 [accepted]
PHST- 2022/04/25 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2022/04/24 20:21 [entrez]
PHST- 2022/04/14 00:00 [pmc-release]
AID - S1569-1993(22)00094-7 [pii]
AID - 10.1016/j.jcf.2022.04.004 [doi]
PST - ppublish
SO  - J Cyst Fibros. 2022 May;21(3):e184-e187. doi: 10.1016/j.jcf.2022.04.004. Epub 
      2022 Apr 14.